Analysts are on the Bearish side about Global Blood Therapeutics, Inc. (NASDAQ:GBT) this week.

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Logo

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Ratings Coverage

Among 2 analysts covering Global Blood Therapeutics (NASDAQ:GBT), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Global Blood Therapeutics had 3 analyst reports since February 22, 2019 according to SRatingsIntel. The rating was maintained by Wedbush with “Outperform” on Tuesday, March 5. The company was maintained on Monday, March 4 by Morgan Stanley. Below is a list of Global Blood Therapeutics, Inc. (NASDAQ:GBT) latest ratings and price target changes.

05/03/2019 Broker: Wedbush Old Rating: Outperform New Rating: Outperform Old Target: $91 New Target: $95 Maintain
04/03/2019 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $55 New Target: $57 Maintain
22/02/2019 Broker: Guggenheim Rating: Buy Initiates Coverage On

The stock increased 0.17% or $0.09 during the last trading session, reaching $52.62. About 584,084 shares traded. Global Blood Therapeutics, Inc. (NASDAQ:GBT) has declined 10.22% since March 17, 2018 and is downtrending. It has underperformed by 14.59% the S&P500.

Global Blood Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood disorders. The company has market cap of $2.96 billion. The Company’s lead product candidate is GBT440, a hemoglobin modifier that binds to hemoglobin molecules, which is in Phase 3 clinical trial for the treatment of sickle cell disease in adult and adolescent patients, as well as evaluates the safety and pharmacokinetics of single and multiple doses of GBT440 on adolescent patients with SCD. It currently has negative earnings. The firm is also involved in conducting Phase 2 clinical trials of GBT440 for the treatment of idiopathic pulmonary fibrosis, which is a hypoxemic pulmonary disorder; and other pre-clinical research and development activities.

More notable recent Global Blood Therapeutics, Inc. (NASDAQ:GBT) news were published by: Seekingalpha.com which released: “Biotechs under pressure, XBI down 1.4% – Seeking Alpha” on February 21, 2019, also Globenewswire.com with their article: “GBT Announces Participation at the 8th Annual SVB Leerink Global Healthcare Conference – GlobeNewswire” published on February 21, 2019, Globenewswire.com published: “GBT Reports Recent Business Progress and Fourth Quarter and Year-End 2018 Financial Results – GlobeNewswire” on February 27, 2019. More interesting news about Global Blood Therapeutics, Inc. (NASDAQ:GBT) were released by: Nasdaq.com and their article: “Health Care Sector Update for 01/30/2019: GBT,SYK,CODX,ACIU – Nasdaq” published on January 30, 2019 as well as Seekingalpha.com‘s news article titled: “FDA accepts GBT’s proposal for accelerated approval pathway for Voxelotor; shares up 42% premarket – Seeking Alpha” with publication date: December 03, 2018.

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Ratings Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.